Stem Cell Therapeutics Corp. (SCT) is a Canada-based biotechnology company-focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is engaged in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological functions lost due to disease or injury. SCT’s product, NTx-265 is a therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin (hCG) and Erythropoietin (EPO), targeting the treatment of stroke.